Aegis Life, Inc.

28/09/2020

At Aegis Life, we are passionate about treating infectious diseases, including SARS-CoV-2. Our team consists of a diverse group of exceptional individuals from all walks of life who bring innovative solutions to the modern approach to vaccines and treatments. To learn more about the team at Aegis Life, Inc., visit: https://aegis.life/leadership/

25/09/2020

Scientists are always exploring the makings of a good vaccine, and Aegis Life is no different. This week's vaccine trait is strong T cell response, which we believe is critical to a vaccine's long-lasting immunity.

24/09/2020

Learn more about what makes a good vaccine from Aegis Life, Inc. CEO Dr. John Lewis, featured on Health Professional Radio.

Dr. Lewis discusses the goal of developing a novel DNA vaccine using its proprietary gene delivery technology, Fusogenix, in the fight against COVID-19

23/09/2020

During the COVID-19 pandemic, scientists and healthcare workers across the nation have risked their lives to help keep people healthy and safe. Here are some words of thanks from Hong Jiang, Founder/Chief Operating Officer of Aegis Life, Inc.

18/09/2020

Scientists are always exploring the makings of a good vaccine, and Aegis Life, Inc. is no different. This week's vaccine trait is Efficacy, a key Aegis Life value as we work to protect human health from persistent infectious diseases.

16/09/2020

Aegis Life, Inc. is proud to be listed on the World Health Organization (WHO) landscape of COVID-19 candidate vaccines, in the DNA category, under our parent company, Entos Pharmaceuticals. To view the full list, visit: https://rb.gy/eifbzv

14/09/2020

Meet Dr. John Lewis, CEO of Aegis Life, Inc. Dr. Lewis is leading Aegis Life in developing genetic vaccines and therapeutics for infectious diseases using the Fusogenix drug delivery system. To learn more about Dr. Lewis, visit: https://aegis.life/leadership/

11/09/2020

At Aegis Life, our core technology includes Fusogenix, a delivery mechanism delivers genetic medicine into the human cell. Fusogenix combines the best of both viral vector and Proteo-Lipid Vehicle (PLV) technologies to deliver genetic cargo or payloads into target cells with excellent tolerability based on animal studies. To learn more about Fusogenix, visit: https://aegis.life/

10/09/2020

We are pleased to announce that we have appointed our co-founder, Dr. Hong Jiang, as our Chief Operating Officer, where she will be responsible for overseeing our business operations, including raising capital, business development and manufacturing scale-up. To learn more, please visit: https://aegis.life/2020/09/09/aegis-life-inc-appoints-hong-jiang-ph-d-as-chief-operating-officer/

01/09/2020

Who are we? At Aegis Life, our mission is to protect human health from the world’s most dangerous and persistent infectious diseases. We will do whatever it takes, leveraging our next-generation vaccines and therapeutics to end the current COVID-19 pandemic and counteract future outbreaks. To learn more about Aegis Life, read the full press release below: https://aegis.life/2020/09/01/aegis-life-inc-launches/